Tonabacase - iNtRON Biotechnology

Drug Profile

Tonabacase - iNtRON Biotechnology

Alternative Names: N-Rephasin® SAL200; SAL200

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iNtRON biotechnology
  • Developer iNtRON Biotechnology; Seoul National University Hospital
  • Class Antibacterials; Coliphages; Endolysins; Endopeptidases; Proteins
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • No development reported Vancomycin-resistant Staphylococcus aureus infections

Most Recent Events

  • 07 Jun 2018 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in South Korea (Intranasal) before June 2018
  • 07 Jun 2018 Pharmacodynamics data from a preclinical studies in Methicillin-resistant Staphylococcus aureus infections presented at the ASM Microbe 2018 (ASMM-2018) (3336477; 3336473)
  • 07 Jun 2018 Updated adverse events data from a phase I trial in healthy volunteers presented at the ASM Microbe 2018 (ASMM-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top